Metabolic Health
By Samir Levin · June 3, 2026 · 6 min read
GLP-1 receptor agonists work. The fat loss data is undeniable — Semaglutide produces 15–17% body weight reduction in the major trials, Tirzepatide pushes past 20%. The problem isn't the drug. The problem is the widespread failure to address what happens alongside the fat loss.
In the landmark STEP trials, approximately 40% of total weight lost on Semaglutide was lean mass — muscle. In a population that is almost universally already sarcopenic, losing 40% of lost weight as muscle is not an acceptable tradeoff. It is a secondary health crisis masked by a primary success metric.
This guide covers the exact titration protocol and the critical nutritional and pharmacological support stack that prevents this from happening.
GLP-1 receptor agonists suppress appetite through multiple central and peripheral mechanisms. The appetite suppression is non-selective — it reduces overall caloric intake regardless of macronutrient composition. In practice, this means most users end up in a severe caloric deficit with dramatically reduced protein intake.
The body's response to both caloric restriction and reduced protein intake in the context of GLP-1 therapy is straightforward: it preferentially oxidizes muscle protein for energy. This is exacerbated by the fact that GLP-1 agonists also slow gastric emptying, which reduces protein absorption rate and efficiency even when protein is consumed.
The solution is not to reduce the effectiveness of the GLP-1 agonist. It is to create conditions that make muscle preservation possible despite the appetite suppression.
Weeks 1–4: 0.25mg subcutaneous weekly
Establishment phase. Allow the GI system to adapt. Most side effects (nausea, GI discomfort) occur at the beginning of each dose escalation. Starting low and slow dramatically improves tolerability.
Weeks 5–8: 0.5mg subcutaneous weekly
First therapeutic dose. Some appetite suppression begins. Monitor protein intake vigilantly — this is where most people first start eating significantly less protein without realizing it.
Weeks 9–12: 1.0mg subcutaneous weekly
Full appetite suppression typically establishes at this dose for most users. Active intervention for protein and nutrient intake becomes critical here.
Weeks 13+: 1.7mg or 2.4mg weekly (if indicated)
Higher doses produce more fat loss but also more aggressive appetite suppression and higher risk of lean mass loss without adequate support. Most users do not need the maximum dose for meaningful results.
Tirzepatide is a dual GIP/GLP-1 agonist with superior efficacy data. The titration is more aggressive due to the different receptor kinetics:
Weeks 1–4: 2.5mg weekly
Weeks 5–8: 5mg weekly
Weeks 9–12: 7.5mg weekly
Week 13+: 10–15mg weekly (based on response and tolerability)
Creatine monohydrate: 5g daily
The most well-documented intervention for lean mass preservation in caloric deficit. Creatine maintains intracellular hydration and supports ATP regeneration in muscle tissue. In the context of GLP-1 therapy, it is not optional — it is the primary defense against muscle loss. The literature is unambiguous on this: creatine supplementation during caloric restriction significantly reduces lean mass loss.
Protein intake: minimum 1.6g/kg bodyweight daily, target 2.0–2.2g/kg
This sounds straightforward until you realize that a user experiencing significant appetite suppression on Semaglutide may genuinely feel full after 50g of food. Protein shakes become a necessity, not a convenience. The goal is to hit protein targets even if total caloric intake is very low.
Omega-3 fatty acids: 3–4g EPA/DHA daily
Anti-catabolic effect on muscle tissue via suppression of the ubiquitin-proteasome pathway. Also addresses the inflammatory cascade that increases with rapid fat oxidation. This is well-documented in the GLP-1 context specifically.
Magnesium glycinate: 400–600mg nightly
GLP-1 agonists affect electrolyte balance. Magnesium deficiency impairs insulin sensitivity and protein synthesis. Most people on aggressive GLP-1 protocols are functionally magnesium deficient within weeks without supplementation.
Resistance training: minimum 3 sessions per week
Non-negotiable. No nutritional intervention fully compensates for the absence of a mechanical stimulus for muscle protein synthesis. Training intensity should be maintained even as volume may need to decrease due to reduced caloric intake. Prioritize compound movements — squat, hinge, press, pull.
For users looking to maximize lean mass preservation and optimize the body composition ratio of the weight lost:
CJC-1295 (no DAC) + Ipamorelin: 100–200mcg each, pre-sleep, fasted
Amplifies the nocturnal growth hormone pulse, supporting lean mass preservation and overnight recovery. Synergistic with GLP-1 therapy — GLP-1 agonists improve insulin sensitivity, CJC/Ipa improves GH pulsatility, together they create an anabolic environment despite caloric restriction.
This combination is detailed in the Metabolic Protocol for the complete framework of GLP-1 + peptide integration.
The clinical data is clear. Users who take GLP-1 agonists without resistance training and adequate protein lose significant muscle. Users who discontinue the medication without having built sufficient muscle mass regain fat at a higher rate because their resting metabolic rate has been further reduced by the muscle loss.
The GLP-1 agonist does its job. The failure is in not doing the work that preserves the value of what the drug achieves.
For the complete protocol including the 16-week phased approach, full peptide integration, and bloodwork monitoring schedule, see the Metabolic Fat Loss & Hormonal Optimization Protocol and the GLP-1 Practical Guide PDF.
GLP-1SemaglutideTirzepatideWeight LossMuscle PreservationCreatine